114. Carmel R, Lau KH, Baylink DJ, et al. Cobalamin and osteoblast-specific proteins. N Engl J Med 1988;319:70-75.
115. Stone KL, Bauer DC, Sellmeyer D, et al. Low serum vitamin B-12 levels are associated with increased hip bone loss in older women: a prospective study [see comment]. J Clin Endocrlnol Metabol 2004;89:1217-1221.
116. Tucker KL, Hannan MT, Qiao N, et al. Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study. J Bone Miner Res 2005;20:152-158.
117. Kang AH,Trelstad RL. A collagen defect in homocystinuria. J Clin Invest 1973;52:2571-2578.
118. Lubec B, Fang-Kircher S, Lubec T, et al. Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 1996;1315:159-162.
119. McLean RR, Jacgues PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons, [see comment]. N Engl J Med 2004;350:2042-2049.
120. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture, [see comment]. N Engl J Med 2004;350:2033-2041.
121. McLean RR, Jacques PF, Selhub J, et al. Plasma В vitamins, homocysteine and their relation with bone loss and hip fracture in elderly men and women. J Clin Endocrin Metab 2008;93:2206-2212.
122. Sato Y Honda Y, Iwamoto J, et al. Effect of folate and meco-balamin on hip fractures in patients with stroke: a randomized controlled trial [see comment] [erratum appears in JAMA. 2006;296:396]. JAMA 2005;293:1082-1088.
123. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine h(2) receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83.
124. Yang Y-X, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-2953.
125. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures [see comment]. CMAJ 2008;179:319-326.
126. De Vries F, Cooper A, Logan R, et al. Fracture risk in patients receiving concomitant bisphosphonate and acid-suppres-sive medication or bisphosphonates alone. Osteoporosis Int 2007;! 85261.
127. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008;28:951-959.
128. Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010;138:896-904.
129. Larsson H, Carlsson E, Mattsson H, et al. Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986;90:391-399.
130. Carlsson E, Larsson H, Mattsson H, et al. Pharmacology and toxicology of omeprazole--with special reference to the effects on the gastric mucosa. Scand J Gastroenterol Suppl 1986;118:31-38.
131. Gillen D, Wirz AA, Ardill JE, et al. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999;116:239-247.
132. Gillen D, Wirz AA, McColl KEL Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment [Erratum appears in Gastroenterology. 2004; 127:694]. Gastroenterology 2004;126:980-988.
133. ReimerC, Sondergaard B, Hilsted L, etal. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009;137:80-87.
134. Niklasson A, Lindstrom L, Simren M, et ai. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010;105:1531-1537.
135. Metz DC, Pilmer BL, Han C, et al. Lack of acid and symptom rebound after withdrawal of 4 to 8 weeks of dexlansoprazole MR or lansoprazole therapy (abstr). Gastroenterology 2010;138, Issue 5, Supplement 1, Page S-652.
136. Rey E, Rodriguez-Artalejo F, Herraiz MA, et al. Gastroesophageal reflux symptoms during and after pregnancy: a longitudinal study. Am J Gastroenterol 2007;102:2395-2400.
137. Ruigomez A, Garcia Rodriguez LA, Cattaruzzi C, et al. Use of ci-metidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 1999;150:476-481.
138. Diav-Citrin O, Arnon J, Shechtman S, etal. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther 2005;21:269-275.
139. Kallen BA. Use of omeprazole during pregnancy--no hazard demonstrated in 955 infants exposed during pregnancy. Eur j Obstet Gynecol Reprod Biol 2001;96:63-68.
140. Nikfar S, Abdollahi M, Moretti ME, et al. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci 2002;47:1526-1529.
141. Lalkin A, Loebstein R, Addis A, et al. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol 1998;179:727-730.
142. Nielsen GL, Sorensen HT,Thu!strup AM, et al. The safety of proton pump inhibitors in pregnancy. Aliment Pharmacol Ther 1999;13:1085-1089.
143. Rhim AD, Hardy JR, Haynes K, et al. Maternal use of proton pump inhibitors during pregnancy is associated with an increased risk for cardiac birth defects: analysis of 208,951 pregnancies from the 0РР0ЯН1Ы database (abstr). Gastroenterology 2010;138:S-63.
144. Alexopoulos E. Drug-induced acute interstitial nephritis. Ren Fail 1998;20:809-819.
145. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int 2000;60:804-817.
146. Ruffenach SJ, Siskind MS, Lien YH. Acute interstitial nephritis due to omeprazole. Am J Med 1992;93:472-473.
147. Sierra F, SuarezM, Rey M, etal. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 2007;26:545-553.
148. Simpson IJ, Marshall MR, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology 2006;11:381-385.
149. Harmark L, van derWiel HE, de Groot MCH, et al. Proton pump inhibitor-induced acute interstitial nephritis. Br J Gin Pharmacol 2007;64:819-823.
150. Myers RP, McLaughlin K, Hollomby DJ. Acute interstitial nephritis due to omeprazole. Am J Gastroenterol 2001;96:3428-3431.
151. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008;103:2890-2907.
152. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001;285:2331-2338.